This article was originally published in RPM Report
Government and industry officials discuss the new drug safety law and the fortunes of the pharmaceutical industry on the campaign trail.
You may also be interested in...
The Reagan-Udall Foundation is an early priority for FDA in implementing the landmark legislation enacted by Congress in 2007. It is also a lightning road for criticism from Congress about the agency's relationship with regulated industry. We asked foundation chairman Mark McClellan for a status report.
It's no surprise that the Democratic Presidential candidates are attacking Medicare Part D. But the really bad news for Big Pharma is that the Republicans don't have anything nice to say about it either. At least for now.
US biopharma companies are warning of significant changes in drug development priorities as they prepare for the implementation of new Medicare pricing measures enacted in 2022. Those changes will have ripple effects on the FDA, which may spark some responses.